Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
Holding DVAX?
Track your performance easily
DVAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.74 - $15.01
Previous Close$12.42
Volume902.69K
Average Volume (3M)2.29M
Market Cap
$1.63B
Enterprise Value$1.12B
Total Cash (Recent Filing)$763.99M
Total Debt (Recent Filing)$250.17M
Price to Earnings (P/E)95.3
Beta0.67
Next Earnings
Feb 20, 2025EPS Estimate
$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding131,454,561
10 Day Avg. Volume3,653,696
30 Day Avg. Volume2,286,645
Standard Deviation0.22
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.35
Price to Sales (P/S)6.05
Price to Cash Flow (P/CF)20.30
P/FCF Ratio20.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.29
Enterprise Value/Gross Profit6.14
Enterprise Value/Ebitda28.44
Forecast
1Y Price Target
$27.67Price Target Upside122.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Dynavax News
PremiumCompany Announcements
Dynavax Technologies Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDynavax has a strong cash position with $764.0M in cash, cash equivalents, and marketable securities as of September 30, 2024.
Market OpportunityThe upgraded U.S. ACIP recommendation for Hepatitis B essentially tripled the eligible population, increasing to 130 million eligible patients.
Market PositionHeplisav-B is the only two-dose adult Hepatitis B vaccine available, providing a unique market position for Dynavax.
Bears Say
Program DiscontinuationThe Tdap program was discontinued due to an undifferentiated profile.
Regulatory ChallengesThe FDA issued a Complete Response Letter due to insufficient data, impacting the sBLA for a four-dose Heplisav-B regimen for adults on hemodialysis.
Sales PerformanceHeplisav-B sales in 3Q24 did not meet the analyst's estimate and consensus, falling short of expectations.
---
Ownership Overview
0.37% Insiders
23.70% Mutual Funds
32.91% Other Institutional Investors
18.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.74 and its highest was $15.01 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Currently, no data Available
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Feb 20, 2025 which is in 87 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Nov 07, 2024. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.007.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is $0.04.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 131,454,560 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.12 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 8.236%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Among the largest hedge funds holding Dynavax Technologies Corp.’s share is Fisher Asset Management LLC. It holds Dynavax Technologies Corp.’s shares valued at 15M.
---
Dynavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.67 (122.79% Upside)
$27.67 (122.79% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 320.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.86%
12-Months-Change
Fundamentals
Return on Equity
3.18%
Trailing 12-Months
Asset Growth
9.15%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DVAX Company Deck
---
DVAX Earnings Call
Q3 2024
0:00 / 0:00
---
DVAX Stock 12 Month Forecast
Average Price Target
$27.67
▲(122.79% Upside)
Technical Analysis
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
12/27 ratings generated profit
1 Year Average Return
-1.77%
reiterated a buy rating 17 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -1.77% per trade.
---